ranirestat

Ranirestat (also known as AS-3201) is an aldose reductase inhibitor being developed for the treatment of diabetic neuropathy by Dainippon Sumitomo Pharma and PharmaKyorin. It has been granted orphan drug status. The drug is to be used orally.

Research

48 papers

Ranirestat Improves Electrophysiologic but not Clinical Measures of Diabetic Polyneuropathy: A Meta-Analysis.Indian journal of endocrinology and metabolism · 2022
Evaluation of ranirestat for the treatment of diabetic neuropathy.Expert opinion on drug metabolism & toxicology · 2014
Pharmacokinetics and Safety of Ranirestat in Patients With Hepatic Impairment.Journal of clinical pharmacology · 2020
Ranirestat as a therapeutic aldose reductase inhibitor for diabetic complications.Expert opinion on investigational drugs · 2008
Ranirestat Improved Nerve Conduction Velocities, Sensory Perception, and Intraepidermal Nerve Fiber Density in Rats with Overt Diabetic Polyneuropathy.Journal of diabetes research · 2019

via PubMed

Wikidata facts

Mass: 418.992

Show 4 more facts

canonical SMILES: C1C(=O)NC(=O)C12C(=O)N(C(=O)C3=CC=CN23)CC4=C(C=C(C=C4)Br)F
chemical formula: C₁₇H₁₁BrFN₃O₄
isomeric SMILES: C1C(=O)NC(=O)[C@@]12C(=O)N(C(=O)C3=CC=CN23)CC4=C(C=C(C=C4)Br)F
Commons category: Ranirestat

Sources (2)

via Wikidata · CC0

~2 min read

Article

5 sections

Contents

Trials
Mechanism of action
Efficacy
See also
References

==Trials== A Canadian Phase III clinical trial has been completed. Phase III trials in Europe and the US started in June 2009 and are expected to complete in April 2013.